氨磺必利与利培酮治疗精神分裂症临床研究  

Clinical Effect of Amisulpride and Risperidone in the Treatment of Schizophrenia

作　　者：邹凯[1] 刘晓伟[1] 袁菁[1] 范洁[1] 奚娟[1] 周兆新[1] 

机构地区：[1]中国江苏省无锡市精神卫生中心,214151

出　　处：《中国健康心理学杂志》2013年第4期489-490,共2页China Journal of Health Psychology

摘　　要：目的比较氨磺必利与利培酮治疗精神分裂症的疗效及安全性。方法将60例精神分裂症患者随机分为氨磺必利组和利培酮组各30例,疗程6周。采用阳性和阴性症状量表(PANSS)及副反应量表(TESS)分别在治疗前、治疗第2、4、6周末分别评估疗效及不良反应。同时于治疗前后检测血清泌乳素(PRL)水平。结果 6周末氨磺必利组和利培酮组PANSS分值均显著下降(t=9.96,10.14;P<0.05),6周末氨磺必利组有效率86.67%,利培酮组有效率93.33%,两组差异无统计学意义。6周末氨磺必利组和利培酮组均出现泌乳素水平显著升高(t=8.79,9.12;P<0.05)。氨磺必利组有10例出现静坐不能,6例出现震颤,7例出现肌强直;利培酮组有4例出现静坐不能,6例出现震颤6例,4例出现肌强直。结论氨磺必利与利培酮疗效相当,能显著改善精神分裂症症状,但在治疗过程要注意锥体外系副反应和泌乳素水平升高等情况。Objective To compare the efficacy and safety of amisulpride and risperidone in the treatment of schizophrenia. Metheds A total of 60 patients with schizophrenia were randomly assigned to amisulpride or risperidone group, and received amisulpride or risperidone for 6 weeks. The efficacy and side effects were assessed with the Positive and Negative Syndrome Scale （PANSS）and Treatment Emergent Symptom Scale（TESS）at week 0,2,4,6. The prelactin （PRL） level was measured at the base- line and the end of study. Results The PANSS scores in both groups decreased significantly after treatment（t= 9.96,10.14 ;P〈 0.05） ,and the clinical response rates were 86.67% and 93.33% respectively. There were no significant differences between both groups （X2= 0.19,P〉 0. 05）. The PRL level were increased significantly as compared to the baseline in both groups （t = 8.79,9.12; P〈 0. 05）. In this 6-week study,askathisia, thereof, hypermyotonia were found in both groups. Conclusion Amisulpride has sim- ilar therapeutic effect to risperidone in treatment of patients with schizophrenia. Amisulpride can cause hyperprolactinemia and in- crease PRL level.

关 键 词：氨磺必利 利培酮 精神分裂症 副反应量表 

分 类 号：R749.3[医药卫生—神经病学与精神病学]